Key facts
- ACET - Adicet Bio, Inc. has 29 insiders with reported activity on this page.
- Net insider value flow over the last year: +$6,016,960.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 29 Insiders of Adicet Bio, Inc.
- Symbol
- ACET on Nasdaq
- Location
- Boston, MA
Change
- Buy value: $11,415,737; sell value: $5,398,776.
- Net share flow: +5,057,120.
Research use
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$6,016,960.
Buys
$11,415,737
Shares: 5,894,384
Insiders: 5
Sells
$5,398,776
Shares: 837,264
Insiders: 8
Net
+$6,016,960
Shares: +5,057,120
Insiders: -3
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 837,264 | $0 | $5,398,776 | -$5,398,776 |
| 3-6 | 894,384 | 0 | $6,415,737 | $0 | +$6,415,737 |
| 6-9 | 5,000,000 | 0 | $5,000,000 | $0 | +$5,000,000 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Adicet Bio, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| RA Capital Healthcare Fund LP | 10%+ Owner | $6,226,197 | +$1,603,934 | +35% | Mixed | 27 Apr 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | $6,226,197 | +$1,603,934 | +35% | Mixed | 27 Apr 2026 |
| Rajeev M. Shah | 10%+ Owner | $6,226,197 | +$1,603,934 | +35% | Mixed | 27 Apr 2026 |
| Peter Kolchinsky | 10%+ Owner | $6,226,197 | +$1,603,934 | +35% | Mixed | 27 Apr 2026 |
| Carl L. Gordon | Director, 10%+ Owner | $941,594 | Mixed | 21 Aug 2024 | ||
| Francesco Galimi | SVP & Chief Medical Officer | $244,322 | Mixed | 05 Jun 2024 | ||
| Aya Jakobovits | Director | $214,323 | Mixed | 21 Aug 2024 | ||
| Lloyd Klickstein | Director | $66,225 | Mixed | 11 Jun 2025 | ||
| Chen Schor | President & CEO, Director | $59,296 | Mixed | 25 Mar 2026 | ||
| Brian Nicholas Harvey | Chief Financial Officer | $43,423 | Mixed | 25 Mar 2026 | ||
| Don Healey | Chief Technology Officer | $29,134 | Mixed | 25 Mar 2026 | ||
| Blake Aftab | Chief Scientific Officer | $25,159 | Mixed | 25 Mar 2026 | ||
| Steve Dubin | Director | $13,847 | Mixed | 11 Jun 2025 | ||
| Jeffrey Chodakewitz | Director | $10,797 | Mixed | 11 Jun 2025 | ||
| Andrew Sinclair | Director | $10,797 | Mixed | 11 Jun 2025 | ||
| Michael Kauffman | Director | $8,437 | Filing P/S | 21 Aug 2024 | ||
| Katie Peng | Director | $7,198 | Mixed | 11 Jun 2025 | ||
| OrbiMed Advisors Israel II Ltd | 10%+ Owner | $0 | -$674,847 | -100% | Mixed | 07 Apr 2026 |
| OrbiMed Israel GP Ltd. | 10%+ Owner | $0 | -$674,847 | -100% | Mixed | 07 Apr 2026 |
| ORBIMED ADVISORS LLC | 10%+ Owner | $0 | +$4,325,153 | Mixed | 07 Apr 2026 | |
| OrbiMed Capital GP V LLC | 10%+ Owner | $0 | -$674,847 | -100% | Mixed | 07 Apr 2026 |
| OrbiMed Israel GP II, L.P. | 10%+ Owner | $0 | -$674,847 | -100% | Mixed | 07 Apr 2026 |
| OrbiMed Capital GP VI LLC | 10%+ Owner | $0 | -$674,847 | -100% | Mixed | 07 Apr 2026 |
| OrbiMed Israel BioFund GP Limited Partnership | 10%+ Owner | $0 | -$674,847 | -100% | Mixed | 07 Apr 2026 |
| OrbiMed Genesis GP LLC | 10%+ Owner | $0 | -$674,847 | -100% | Mixed | 07 Apr 2026 |
| Julia D. Maltzman | Chief Medical Officer | Mixed | 25 Mar 2026 | |||
| Michael Grissinger | Director | Mixed | 17 Apr 2025 | |||
| Bastiano Sanna | Director | Mixed | 14 Aug 2023 | |||
| Stewart Abbot | Former Chief Scientific and Operating Officer | Mixed | 11 Jun 2021 |
Top shareholders of Adicet Bio, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
3/4/5
13F
|
10%+ Owner · Company |
12%
|
1,182,624
|
$8,834,201 | +$1,661,231 | 17 Feb 2026 | |
| ORBIMED ADVISORS LLC |
13D/G
13F
|
Company |
8.8%
|
844,787
|
$7,113,107 | -$117,272,169 | 08 Apr 2026 | |
| FRANKLIN RESOURCES INC |
13D/G
13F
|
Company |
6.5%
|
626,571
|
$5,238,572 | $0 | 31 Dec 2025 | |
| Woodline Partners LP |
13D/G
13F
|
Company |
3.3%
|
313,124
|
$2,132,374 | -$2,123,876 | 31 Mar 2026 | |
| TANG CAPITAL MANAGEMENT LLC |
13D/G
|
— |
0.1%
|
6,158
|
$51,050 | $0 | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
4%
|
381,823
|
$2,600,215 | — | 31 Mar 2026 | |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
|
Company |
3.5%
|
336,524
|
$2,291,728 | — | 31 Mar 2026 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
2.9%
|
274,375
|
$1,868,494 | — | 31 Mar 2026 | |
| Prosight Management, LP |
13F
|
Company |
2.6%
|
250,244
|
$1,704,162 | — | 31 Mar 2026 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
2.5%
|
232,591
|
$1,583,945 | — | 31 Mar 2026 | |
| Stonepine Capital Management, LLC |
13F
|
Company |
2.3%
|
221,955
|
$1,511,514 | — | 31 Mar 2026 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
2.1%
|
203,799
|
$1,387,871 | — | 31 Mar 2026 | |
| Carlyle Group Inc. |
13F
|
Company |
1.9%
|
184,295
|
$1,255,048 | — | 31 Mar 2026 | |
| NEXTBio Capital Management LP |
13F
|
Company |
1.7%
|
157,827
|
$1,074,802 | — | 31 Mar 2026 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
1.2%
|
118,138
|
$802,000 | — | 31 Mar 2026 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.1%
|
101,135
|
$689,043 | — | 31 Mar 2026 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.99%
|
93,812
|
$638,860 | — | 31 Mar 2026 | |
| Burkehill Global Management, LP |
13F
|
Company |
0.66%
|
62,500
|
$425,625 | — | 31 Mar 2026 | |
| REGENERON PHARMACEUTICALS, INC. |
13F
|
Company |
0.63%
|
60,511
|
$412,080 | — | 31 Mar 2026 | |
| Rangeley Capital, LLC |
13F
|
Company |
0.59%
|
56,000
|
$381,360 | — | 31 Mar 2026 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.57%
|
53,827
|
$366,562 | — | 31 Mar 2026 | |
| VANGUARD FIDUCIARY TRUST CO |
13F
|
Company |
0.53%
|
50,334
|
$342,775 | — | 31 Mar 2026 | |
| Trexquant Investment LP |
13F
|
Company |
0.46%
|
43,666
|
$297,365 | — | 31 Mar 2026 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.45%
|
43,106
|
$293,552 | — | 31 Mar 2026 | |
| RBF Capital, LLC |
13F
|
Company |
0.41%
|
38,582
|
$262,743 | — | 31 Mar 2026 | |
| UBS Group AG |
13F
|
Company |
0.4%
|
38,368
|
$261,286 | — | 31 Mar 2026 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.39%
|
37,084
|
$252,542 | — | 31 Mar 2026 | |
| BlackRock, Inc. |
13F
|
Company |
0.39%
|
36,585
|
$249,144 | — | 31 Mar 2026 | |
| STATE STREET CORP |
13F
|
Company |
0.38%
|
36,222
|
$246,672 | — | 31 Mar 2026 | |
| BARCLAYS PLC |
13F
|
Company |
0.26%
|
25,000
|
$170,250 | — | 31 Mar 2026 | |
| JOHNSON & JOHNSON |
13F
|
Company |
0.24%
|
22,779
|
$155,125 | — | 31 Mar 2026 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.2%
|
19,200
|
$130,752 | — | 31 Mar 2026 | |
| XTX Topco Ltd |
13F
|
Company |
0.2%
|
19,126
|
$130,248 | — | 31 Mar 2026 | |
| OCCUDO QUANTITATIVE STRATEGIES LP |
13F
|
Company |
0.16%
|
15,100
|
$114,005 | — | 31 Mar 2026 | |
| Vontobel Holding Ltd. |
13F
|
Company |
0.15%
|
14,247
|
$97,022 | — | 31 Mar 2026 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.11%
|
10,778
|
$73,398 | — | 31 Mar 2026 | |
| Vanguard Global Advisers, LLC |
13F
|
Company |
0.06%
|
5,221
|
$35,555 | — | 31 Mar 2026 | |
| MORGAN STANLEY |
13F
|
Company |
0.04%
|
3,493
|
$23,787 | — | 31 Mar 2026 | |
| FNY Investment Advisers, LLC |
13F
|
Company |
0.03%
|
3,200
|
$21,000 | — | 31 Mar 2026 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.02%
|
1,687
|
$11,000 | — | 31 Mar 2026 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
1,421
|
$9,677 | — | 31 Mar 2026 | |
| SIMPLEX TRADING, LLC |
13F
|
Company |
0.01%
|
1,393
|
$9,486 | — | 31 Mar 2026 | |
| Avion Wealth |
13F
|
Company |
0%
|
246
|
$1,000 | — | 31 Mar 2026 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0%
|
50
|
$340 | — | 31 Mar 2026 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
19
|
$129 | — | 31 Mar 2026 | |
| NATIONAL BANK OF CANADA /FI/ |
13F
|
Company |
0%
|
17
|
$115 | — | 31 Mar 2026 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
8
|
$49 | — | 31 Mar 2026 | |
| Caitong International Asset Management Co., Ltd |
13F
|
Company |
0%
|
3
|
$20 | — | 31 Mar 2026 | |
| DANSKE BANK A/S |
13F
|
Company |
0%
|
1
|
$7 | — | 31 Mar 2026 | |
| Peter Kolchinsky |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
2,335,457
mixed-class rows
|
$6,226,197 | +$1,603,934 | 27 Apr 2026 |
Recent Insider Transactions by Companies or Individuals for Adicet Bio, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | ACET | Common Stock | Other | -21.1% | -250,000 | 932,624 | 27 Apr 2026 | See footnotes | ||
| RA CAPITAL MANAGEMENT, L.P. | ACET | Common Stock | Other | -21.1% | -250,000 | 932,624 | 27 Apr 2026 | See footnotes | ||
| Ra Capital Management, L.P. | ACET | Common Stock | Other | -21.1% | -250,000 | 932,624 | 27 Apr 2026 | See footnotes | ||
| Ra Capital Management, L.P. | ACET | Common Stock | Other | -21.1% | -250,000 | 932,624 | 27 Apr 2026 | See footnotes | ||
| RA CAPITAL MANAGEMENT, L.P. | ACET | Pre-Funded Warrant (Right to Buy) | Other | 21.7% | 250,000 | 1,402,833 | 27 Apr 2026 | See footnotes | ||
| RA CAPITAL MANAGEMENT, L.P. | ACET | Pre-Funded Warrant (Right to Buy) | Other | 21.7% | 250,000 | 1,402,833 | 27 Apr 2026 | See footnotes | ||
| Ra Capital Management, L.P. | ACET | Pre-Funded Warrant (Right to Buy) | Other | 21.7% | 250,000 | 1,402,833 | 27 Apr 2026 | See footnotes | ||
| Ra Capital Management, L.P. | ACET | Pre-Funded Warrant (Right to Buy) | Other | 21.7% | 250,000 | 1,402,833 | 27 Apr 2026 | See footnotes | ||
| Orbimed Advisors Llc | ACET | Common Stock | Sale | -100% | $468,082 | $6.42 | -72,939 | 0 | 08 Apr 2026 | See footnotes |
| Orbimed Advisors Llc | ACET | Common Stock | Sale | -100% | $468,082 | $6.42 | -72,939 | 0 | 08 Apr 2026 | See footnotes |
| ORBIMED ADVISORS LLC | ACET | Common Stock | Sale | -100% | $468,082 | $6.42 | -72,939 | 0 | 08 Apr 2026 | See footnotes |
| Orbimed Advisors Llc | ACET | Common Stock | Sale | -100% | $468,082 | $6.42 | -72,939 | 0 | 08 Apr 2026 | See footnotes |
| Orbimed Advisors Llc | ACET | Common Stock | Sale | -100% | $468,082 | $6.42 | -72,939 | 0 | 08 Apr 2026 | See footnotes |
| Orbimed Advisors Llc | ACET | Common Stock | Sale | -100% | $468,082 | $6.42 | -72,939 | 0 | 08 Apr 2026 | See footnotes |
| Orbimed Advisors Llc | ACET | Common Stock | Sale | -100% | $468,082 | $6.42 | -72,939 | 0 | 08 Apr 2026 | See footnotes |
| Orbimed Advisors Llc | ACET | Common Stock | Sale | -100% | $468,082 | $6.42 | -72,939 | 0 | 08 Apr 2026 | See footnotes |
| Orbimed Advisors Llc | ACET | Common Stock | Sale | -49.4% | $206,765 | $6.52 | -31,719 | 32,523 | 07 Apr 2026 | See footnotes |
| Orbimed Advisors Llc | ACET | Common Stock | Sale | -49.4% | $206,765 | $6.52 | -31,719 | 32,523 | 07 Apr 2026 | See footnotes |
| ORBIMED ADVISORS LLC | ACET | Common Stock | Sale | -49.4% | $206,765 | $6.52 | -31,719 | 32,523 | 07 Apr 2026 | See footnotes |
| Orbimed Advisors Llc | ACET | Common Stock | Sale | -49.4% | $206,765 | $6.52 | -31,719 | 32,523 | 07 Apr 2026 | See footnotes |
| Orbimed Advisors Llc | ACET | Common Stock | Sale | -49.4% | $206,765 | $6.52 | -31,719 | 32,523 | 07 Apr 2026 | See footnotes |
| Orbimed Advisors Llc | ACET | Common Stock | Sale | -49.4% | $206,765 | $6.52 | -31,719 | 32,523 | 07 Apr 2026 | See footnotes |
| Orbimed Advisors Llc | ACET | Common Stock | Sale | -49.4% | $206,765 | $6.52 | -31,719 | 32,523 | 07 Apr 2026 | See footnotes |
| Orbimed Advisors Llc | ACET | Common Stock | Sale | -49.4% | $206,765 | $6.52 | -31,719 | 32,523 | 07 Apr 2026 | See footnotes |
| Brian Nicholas Harvey | ACET | Stock Option (Right to Buy) | Award | 43,361 | 43,361 | 25 Mar 2026 | Direct | |||
| Chen Schor | ACET | Stock Option (Right to Buy) | Award | 468,555 | 468,555 | 25 Mar 2026 | Direct | |||
| Julia D. Maltzman | ACET | Stock Option (Right to Buy) | Award | 72,555 | 72,555 | 25 Mar 2026 | Direct | |||
| Don Healey | ACET | Stock Option (Right to Buy) | Award | 43,361 | 43,361 | 25 Mar 2026 | Direct | |||
| Blake Aftab | ACET | Stock Option (Right to Buy) | Award | 72,555 | 72,555 | 25 Mar 2026 | Direct | |||
| RA CAPITAL MANAGEMENT, L.P. | ACET | Common Stock | Purchase | 6.75% | $543,440 | $7.27 | 74,751 | 1,182,624 | 20 Feb 2026 | See footnotes |
| RA CAPITAL MANAGEMENT, L.P. | ACET | Common Stock | Purchase | 6.75% | $543,440 | $7.27 | 74,751 | 1,182,624 | 20 Feb 2026 | See footnotes |
| Ra Capital Management, L.P. | ACET | Common Stock | Purchase | 6.75% | $543,440 | $7.27 | 74,751 | 1,182,624 | 20 Feb 2026 | See footnotes |
| Ra Capital Management, L.P. | ACET | Common Stock | Purchase | 6.75% | $543,440 | $7.27 | 74,751 | 1,182,624 | 20 Feb 2026 | See footnotes |
| RA CAPITAL MANAGEMENT, L.P. | ACET | Common Stock | Purchase | 7.19% | $535,472 | $7.21 | 74,268 | 1,107,873 | 19 Feb 2026 | See footnotes |
| RA CAPITAL MANAGEMENT, L.P. | ACET | Common Stock | Purchase | 7.19% | $535,472 | $7.21 | 74,268 | 1,107,873 | 19 Feb 2026 | See footnotes |
| Ra Capital Management, L.P. | ACET | Common Stock | Purchase | 7.19% | $535,472 | $7.21 | 74,268 | 1,107,873 | 19 Feb 2026 | See footnotes |
| Ra Capital Management, L.P. | ACET | Common Stock | Purchase | 7.19% | $535,472 | $7.21 | 74,268 | 1,107,873 | 19 Feb 2026 | See footnotes |
| RA CAPITAL MANAGEMENT, L.P. | ACET | Common Stock | Purchase | 7.78% | $525,022 | $7.04 | 74,577 | 1,033,605 | 18 Feb 2026 | See footnotes |
| RA CAPITAL MANAGEMENT, L.P. | ACET | Common Stock | Purchase | 7.78% | $525,022 | $7.04 | 74,577 | 1,033,605 | 18 Feb 2026 | See footnotes |
| Ra Capital Management, L.P. | ACET | Common Stock | Purchase | 7.78% | $525,022 | $7.04 | 74,577 | 1,033,605 | 18 Feb 2026 | See footnotes |
| Ra Capital Management, L.P. | ACET | Common Stock | Purchase | 7.78% | $525,022 | $7.04 | 74,577 | 1,033,605 | 18 Feb 2026 | See footnotes |
| Blake Aftab | ACET | Common Stock | Tax liability | -15.2% | -535 | 2,981 | 24 Jan 2026 | Direct | ||
| Don Healey | ACET | Common Stock | Tax liability | -13.4% | -535 | 3,452 | 24 Jan 2026 | Direct | ||
| Brian Nicholas Harvey | ACET | Common Stock | Tax liability | -9.59% | -546 | 5,145 | 24 Jan 2026 | Direct | ||
| Chen Schor | ACET | Common Stock | Tax liability | -20.5% | -1,755 | 6,820 | 24 Jan 2026 | Direct | ||
| Orbimed Advisors Llc | ACET | Common Stock | Purchase | 124.2% | $5,000,000 | $1.00 | 5,000,000 | 9,026,359 | 08 Oct 2025 | See footnotes |
| Lloyd Klickstein | ACET | Common Stock | Award | 5.75% | 5,900 | 108,566 | 11 Jun 2025 | Direct | ||
| Lloyd Klickstein | ACET | Stock Option (Right to Buy) | Award | 26,400 | 26,400 | 11 Jun 2025 | Direct | |||
| Jeffrey Chodakewitz | ACET | Common Stock | Award | 50% | 5,900 | 17,700 | 11 Jun 2025 | Direct | ||
| Jeffrey Chodakewitz | ACET | Stock Option (Right to Buy) | Award | 26,400 | 26,400 | 11 Jun 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.